Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2024-09-03 Regulatory Filings
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Statement of CDIs on issue - RMD 3 pages 12.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4A - Statement of CDIs on issue' and details the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly statements of securities issued, net differences, and reasons for changes such as transfers, stock options, employee stock purchase plans, and share repurchases. The document is a regulatory announcement related to securities on issue rather than a financial report or earnings release. It is relatively short (3044 characters) and does not contain financial statements or management discussion. This type of document corresponds to a Regulatory Filing (RNS) as it is a general regulatory announcement about securities issued and changes in share capital but does not fit into more specific categories like Share Issue/Capital Change (SHA) because it is a standard Appendix 4A statement required by ASX for securities on issue.
2024-09-03 English
Director Appointment/Resignation 6 pages 63.4KB
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2024, by ResMed Inc. The key content is the appointment of Christopher DelOrefice to the company's board of directors, including details about his background and role. The document specifically falls under Item 5.02, which relates to changes in directors or certain officers. There is no financial data or earnings information, nor is this a report or presentation. The document is clearly an announcement of a board/management change, matching the category for Board/Management Information (MANG).
2024-08-18 English
Update - Dividend/Distribution - RMD 4 pages 16.7KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and provides detailed information about a dividend payment, including the dividend amount, currency, record date, payment date, withholding tax rates, and exchange rates. It is an update to a previous announcement regarding the foreign exchange rate for the upcoming dividend. The content focuses exclusively on dividend details and payment logistics rather than financial results or reports. Therefore, this document fits the category of a Notice of Dividend Amount (DIV). The document length and detail confirm it is not merely a brief announcement or a report publication notice but a full dividend notification.
2024-08-18 English
ResMed Form 10-k Annual Report 110 pages 1.1MB
Annual Report Classification · 100% confidence The document is titled 'FORM 10-K' and explicitly states it is an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended June 30, 2024. It includes detailed sections typical of a 10-K filing such as Business, Risk Factors, Legal Proceedings, Management's Discussion and Analysis, Financial Statements, and Executive Compensation. The length of the document (15,000 characters) and the presence of comprehensive financial and business information confirm it is the full annual report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2024
2024-08-11 English
Statement of CDIs on issue - RMD 3 pages 12.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4A - Statement of CDIs on issue' and details the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly data for July 2024, changes in securities, and reasons for changes such as transfers, stock options, employee stock purchase plans, and share repurchases. The document is a regulatory announcement related to securities issued and changes in share capital but does not contain financial statements, management discussion, or detailed financial results. It is a formal regulatory filing about securities on issue, consistent with Appendix 4A filings on the ASX, which are typically classified as Regulatory Filings (RNS). The document length is 3043 characters, which is relatively short and focused on securities data rather than a full report or announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-04 English
ResMed Announces Results for the Fourth Quarter of FY2024 10 pages 177.3KB
Earnings Release Classification · 95% confidence The document is a detailed announcement of ResMed Inc.'s financial results for the fourth quarter and full fiscal year 2024, including revenue, operating profit, earnings per share, cash flow, and dividend information. It contains unaudited condensed consolidated statements of operations and balance sheets with substantive financial data and analysis. The document also mentions a webcast of the earnings call and includes management commentary on business performance and outlook. The presence of comprehensive quarterly and annual financial data, management discussion, and earnings highlights indicates this is a quarterly earnings release rather than a full annual report or other filing. The document length (15,000 characters) and detailed financial tables confirm it is not a brief announcement or certification. Therefore, the document fits the definition of an Earnings Release (ER). Q4 2024
2024-08-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.